Download PDF
Semin Thromb Hemost 2002; 28(s2): 033-040
DOI: 10.1055/s-2002-32317
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Unresolved Issues in the Prevention and Treatment of Venous Thromboembolism

Giancarlo Agnelli
  • University of Perugia, Perugia, Italy
Further Information

Publication History

Publication Date:
19 June 2002 (online)

    Permissions and Reprints

ABSTRACT

Venous thromboembolism (VTE) is a major health problem. Anticoagulation can significantly decrease the morbidity and mortality associated with VTE. Heparin and coumarin derivatives have been the standard of care for the last 50 years, and the development of low-molecular-weight heparin preparations has significantly improved the prevention and treatment of venous thromboembolic disease. With these advances, investigators are now able to address some of the unresolved issues in antithrombotic therapy, including the search for the optimal antithrombotic agent in high-risk patients, the optimal timing of thromboprophylaxis initiation in the surgical population, and the duration of prophylaxis for the prevention of initial and recurrent VTE events. Clinical trials have begun to investigate many of these issues, and the resulting data have already contributed to improving the management of patients with a high risk of VTE.

KEYWORDS

Venous thromboembolism - prophylaxis - heparin - low-molecular-weight heparin - factor Xa inhibitors

REFERENCES

  • 1 Heit J A, Melton III J L, Lohse C M. Incidence of venous thromboembolism in hospitalized patients vs community residents.  Mayo Clin Proc . 2001;  76 1102-1110
    CrossrefPubMedGoogle Scholar
  • 2 Moser K M, Fedullo P F, LitteJohn J K, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis.  JAMA . 1994;  271 223-225
    CrossrefPubMedGoogle Scholar
  • 3 Heit J A, Silverstein M D, Mohr D N. Predictors of survival after deep vein thrombosis and pulmonary embolism. A population-based, cohort study.  Arch Intern Med . 1999;  159 445-453
    CrossrefPubMedGoogle Scholar
  • 4 Carson J L, Kelley M A, Duff A. The clinical course of pulmonary embolism.  N Engl J Med . 1992;  326 1240-1245
    CrossrefPubMedGoogle Scholar
  • 5 PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED).  JAMA . 1990;  263 2753-2759
    Google Scholar
  • 6 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism.  Chest . 2001;  119(suppl) 132S-175S
    CrossrefPubMedGoogle Scholar
  • 7 Bauer K. Selective inhibition of coagulation factors: advancing antithrombotic therapy.  Semin Thromb Hemost . 2002;  28(Suppl 2) 15-24
    PubMedGoogle Scholar
  • 8 Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data.  Thromb Res . 2001;  102 295-309
    CrossrefPubMedGoogle Scholar
  • 9 Rocha E, Martinez-González M A, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis?.  <~>A meta-analysis. Haematologica . 2000;  85 935-942
    PubMedGoogle Scholar
  • 10 Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis.  Drugs . 1996;  52(Suppl 7) 30-37
    PubMedGoogle Scholar
  • 11 van der Heijden F J, Prins M H, Büller H R. Low-molecular-weight heparins: are they interchangeable?.  Haemostasis . 2000;  30(Suppl 2) 148-157
    CrossrefPubMedGoogle Scholar
  • 12 Heit J A, Silverstein M D, Mohr D N. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.  Arch Intern Med . 2000;  160 809-815
    CrossrefPubMedGoogle Scholar
  • 13 Price D T, Ridker P M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.  Ann Intern Med . 1997;  127 895-903
    PubMedGoogle Scholar
  • 14 Weitz J I, Hirsh J. New anticoagulant drugs.  Chest . 2001;  119(Suppl) 95S-107S
    CrossrefPubMedGoogle Scholar
  • 15 Lee A, Agnelli G, Büller H. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.  Circulation . 2001;  104 74-78
    PubMedGoogle Scholar
  • 16 Heit J A, Colwell C W, Francis C W. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study.  Arch Intern Med . 2001;  161 2215-2221
    CrossrefPubMedGoogle Scholar
  • 17 Eriksson B I, Arfwidsson A-C, Frison L. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I.  Thromb Haemost . 2002;  87 231-237
    PubMedGoogle Scholar
  • 18 Eriksson B I, Ögren M, Agnelli G. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement [abstract OC1638]. Thromb Haemost 2001; July(Suppl). Available on CD-ROM published by Excerpta Medica Medical Communications
    Google Scholar
  • 19 Francis C W, Davidson B L, Berkowitz S D. Randomized, double-blind, comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA) [abstract OC44]. Thromb Haemost 2001;July(Suppl). Available on CD-ROM published by Excerpta Medica Medical Communications
    Google Scholar
  • 20 Eriksson B I, Lindbratt S, Kälebo P. Methro II: dose-response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or total knee replacement [abstract 38].  Haemostasis . 2000;  30(Suppl 1) 20-21
    PubMedGoogle Scholar
  • 21 Donat F, Duret J P, Santoni A. Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile [abstract P3094]. Thromb Haemost 2001;July(Suppl). Available on CD-ROM published by Excerpta Medica Medical Communications
    Google Scholar
  • 22 Turpie A GG, Bauer K A, Eriksson B I, Lassen M R, for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.  Lancet . 2002;  359 1721-26
    CrossrefPubMedGoogle Scholar
  • 23 Lassen M R, Bauer K A, Eriksson B I, Turpie A GG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.  Lancet . 2002;  359 1715-20
    CrossrefPubMedGoogle Scholar
  • 24 Eriksson B I, Bauer K A, Lassen M R, Turpie A GG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med . 2001;  345 1298-1304
    CrossrefPubMedGoogle Scholar
  • 25 Bauer K A, Eriksson B I, Lassen M R, Turpie A GG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med . 2001;  345 1305-1310
    CrossrefPubMedGoogle Scholar
  • 26 Turpie A GG. Overview of the clinical results of pentasaccharide in major orthopedic surgery.  Haematologica . 2001;  86(Suppl 11) 59-62
    PubMedGoogle Scholar
  • 27 Simoons M L. The PENTUA study: double-blind dose-ranging study of fondaparinux (pentasaccharide) in unstable angina. 2001. Available at: http://www.sessionsonline.org/ Html src/summary.asp?styId=32&uid=&ld=11/15/01. Accessed April 18, 2002
    Google Scholar
  • 28 Coussement P K, Bassand J-P, Convens C. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTA-LYSE study.  Eur Heart J . 2001;  22 1716-1724
    CrossrefPubMedGoogle Scholar
  • 29 The REMBRANDT Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation.  Circulation . 2000;  102 2726-2731
    PubMedGoogle Scholar
  • 30 Hull R D, Brant R F, Pineo G F. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement.  Arch Intern Med . 1999;  159 137-141
    CrossrefPubMedGoogle Scholar
  • 31 Agnelli G, Mancini G B, Biagini D. The rationale for long-term prophylaxis of venous thromboembolism.  Orthopedics . 2000;  23(Suppl 6) s643-s646
    PubMedGoogle Scholar
  • 32 Bergqvist D, Benoni G, Björgell O. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.  N Engl J Med . 1996;  335 696-700
    CrossrefPubMedGoogle Scholar
  • 33 Planes A, Vochelle N, Darmon J-Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo.  Lancet . 1996;  348 224-228
    CrossrefPubMedGoogle Scholar
  • 34 Dahl O E, Andreassen G, Aspelin T. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).  Thromb Haemost . 1997;  77 26-31
    PubMedGoogle Scholar
  • 35 Lassen M R, Borris L C, Anderson B S. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study.  Thromb Res . 1998;  89 281-287
    CrossrefPubMedGoogle Scholar
  • 36 Hull R D, Pineo G F, Francis C. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. A double-blind, randomized comparison.  Arch Intern Med . 2000;  160 2208-2215
    CrossrefPubMedGoogle Scholar
  • 37 Comp P C, Spiro T E, Friedman R J. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement.  J Bone Joint Surg Am . 2001;  83 336-345
    CrossrefPubMedGoogle Scholar
  • 38 Hull R D, Pineo G F, Stein P D. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.  Ann Intern Med . 2001;  135 858-869
    CrossrefPubMedGoogle Scholar
  • 39 Cohen A T, Bailey C S, Alikhan R, Cooper D J. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty-a meta-analysis.  Thromb Haemost . 2001;  85 940-941
    PubMedGoogle Scholar
  • 40 Heit J A, Elliott C G, Trowbridge A A. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial.  Ann Intern Med . 2000;  132 853-861
    PubMedGoogle Scholar
  • 41 Eikelboom J W, Quinlan D J, Douketis J D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.  Lancet . 2001;  358 9-15
    CrossrefPubMedGoogle Scholar
  • 42 Agnelli G, Taliani M R, Verso M. Building effective prophylaxis of deep vein thrombosis in the outpatient setting.  Blood Coagul Fibrinolysis . 1999;  10(Suppl 2) S29-S35
    PubMedGoogle Scholar
  • 43 Agnelli G, Prandoni P, Santamaria M G. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis.  N Engl J Med . 2001;  345 165-169
    PubMedGoogle Scholar
  • 44 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease.  Chest . 2001;  119 (Suppl 1) 176S-193S
    CrossrefPubMedGoogle Scholar
  • 45 Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med . 1999;  340 901-907
    PubMedGoogle Scholar